In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G gets into sterols

This article was originally published in The Tan Sheet

Executive Summary

Procter & Gamble signs an agreement with agribusiness and food firm Bunge Limited and manufacturer Peter Cremer for the production and marketing of phytosterol ingredients for foods and pharmaceuticals, Bunge announces Nov. 10. The alliance "creates an efficient, integrated supply chain based on Bunge's raw material supply, P&G's marketing and sales expertise and Peter Cremer's manufacturing capabilities," the firm says. Bunge estimates global demand for phytosterols will exceed 10,000 tons by 2008, representing a market value of $200-$250 mil. FDA approved the expanded use of a phytosterol CHD health claim last year (1"The Tan Sheet" Feb. 24, 2003, p. 4)...

You may also be interested in...



Phytosterol CHD Health Claim Expanded Interim Use Permitted By FDA

FDA will allow the use of a phytosterol heart health claim on a broader range of foods, beverages and dietary supplements while it completes a final rule on the issue, according to a Feb. 14 open letter posted on the agency's Web site

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS097526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel